Management of patients with gynecologic cancer by serum sialic acid determination

Y Shimizu, Yoshio Shimizu, Shimizu Y, Hasumi K, Katsuhiko Hasumi, K Hasumi, Masubuchi K, K Masubuchi, Kazumasa Masubuchi, Okudaira Y, Y Okudaira, Yoshio Okudaira
Gynecologic Oncology · 1989 · doi:10.1016/0090-8258(89)90558-1 · PMID:2703183
case-report OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

Serum sialic acid levels were elevated in gynecologic cancer patients compared to healthy females, correlating with prognosis and serving as a useful nonspecific follow-up marker.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

With an enzymatic technique, serum sialic acid (SA) levels were determined in patients with gynecologic tumors. Since the SA level for healthy females was 57.4 +/- 7.3 mg/dl, we set the upper normal limit of this parameter at 72 mg/dl. The SA level became larger in ascending order of uterine myoma, benign ovarian tumor, cervical cancer, corpus cancer, and ovarian cancer. The SA level proved to be significantly higher in cancer patients showing poor prognosis than in those having good prognosis irrespective of the category of therapy and it reflected well the clinical course of cancer patients. In patients who receive a combination therapy and need to be followed up for a long term, complete follow-up is sometimes impossible with tumor-derived markers alone. Even in such cases, the sialic acid level will work as a useful follow-up marker because it is nonspecific to histologic types of cancer.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Biomarkers, Tumor Genital Neoplasms, Female Sialic Acids Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adolescent Adult Aged Biomarkers, Tumor Combined Modality Therapy Endometriosis Endometriosis Endometriosis Endometriosis Female Genital Neoplasms, Female Genital Neoplasms, Female Genital Neoplasms, Female

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (13)

Source provenance

crossref
last seen: 2026-05-16T01:00:19.746669+00:00
europepmc
last seen: 2026-08-07T06:07:27.085738+00:00
pubmed
last seen: 2026-05-13T22:09:15.954262+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine